Navigation Links
AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1,Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV,Irradiated Skin Cells

Clinical Data Presented at the Society for Investigative Dermatology

FREEPORT, N.Y., May 16, 2007 /PRNewswire-FirstCall/ -- AGI Dermatics today announced new clinical research that the 8-oxo-guanine DNA glycosylase (OGG1) encapsulated in liposomes enhances DNA repair and reduces MMP-1 and TNF-alpha in UV irradiated skin cells. The data was presented at the 68th Annual Meeting of the Society for Investigative Dermatology, May 9 - 12, in Los Angeles, CA.

"Our clinical study suggests that OGGI liposomes enhance DNA repair in skin cells," said Daniel Yarosh, PhD, President, AGI Dermatics. "This is particularly exciting when we consider that existing data shows that 8-oxo- guanine causes the most significant damage to mitochondrial DNA, which manifests as nearly all signs of premature aging."

The study examined the question of, if by damaging DNA with reactive oxygen species (ROS) would there be an increase of either/both matrix metalloproteinase-1 (MMP-1) and tumor necrosis factor, two factors known to play roles in photoaging. The formation of 8-oxo-G is induced by ROS from UVA irradiation, cigarette smoke, environmental stressors, endogenous enzymatic peroxidation reactions and normal mitochondrial metabolism. Those mentioned account for nearly all of the symptoms of premature skin aging. Long-term exposure consequences include photodamage, fine lines and wrinkles.

Natural cellular repair of the oxidative damage entails complete removal of 8-oxo-G from DNA via the enzyme OGGI. For the test, OOGI encapsulated in liposomes showed that the delivery of this enzyme into fibroblasts increases the rate of repair of 8-oxo-G, and reduces mitochondrial toxicity and analyzed mRNA content and protein secretion of MMP-1 and TNF-alpha, with real-time RT- PCR and ELISA.

Normal human dermal fibroblasts (NHDF) were irradiated with solar- stimulating (ss) UV (UVA340 bulb) to induce MMP-1. Following irra diation, cells were treated with 1ug/mL OGG1 liposomes for up to 48 hours. The study then looked at the results of "repair by damaging" the DNA. The treatment of ssUV stimulated NHEK results in an increased TNF-alpha mRNA expression after 24 hours and TNF secretion after 48 hours. Both ssUV-induced TNF- mRNA and secreted protein were reduced by 50% following OGG1 liposome treatment.

In conclusion, these results indicate that treatment of dermal fibroblasts and epidermal keratinocytes with OGG1 liposomes enhance DNA repair, leads to a reduction in the expression and/or secretion of stress responses proteins such as ssUV-induced MMP-1 and ssUV-induced TNF-a mRNA.

AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Remergent DNA Repair Formula and Antioxidant Refoliator both contain Roxomes, liposomes encapsulating OGG1, which protect the cells genetic material from ROS.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. www.agiderm.com

CONTACT: Courtney McGeever, +1-212-317-1462, for AGI Dermatics

Web site: http://www.agiderm.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):